---
title: "Oligonucleotides"
id: "251"
type: "page"
slug: "oligonucleotides"
published_at: "2025-07-10T11:33:38+00:00"
modified_at: "2026-04-17T09:36:48+00:00"
url: "https://innocorepharma.com/drug-modalities/oligonucleotides/"
markdown_url: "https://innocorepharma.com/drug-modalities/oligonucleotides.md"
---

Drug modalities

# Oligonucleotides – engineering the next generation of long-acting, high impact oligonucleotide therapeutics

Oligonucleotides – short, synthetic strands of nucleic acids – are gaining momentum as powerful therapeutic agents to treat a wide range of diseases. They are not naturally suited to long-acting dosage forms since they are inherently instable, susceptible to enzymatic degradation and poor cellular uptake.

## About Oligonucleotides

Oligonucleotides – short, synthetic strands of nucleic acids – are gaining momentum as powerful therapeutic agents to treat a wide range of diseases. They are not naturally suited to long-acting dosage forms since they are inherently instable, susceptible to enzymatic degradation and poor cellular uptake.

SynBiosys®, our advanced polymer platform, protects these sensitive molecules, extending their therapeutic exposure, and allowing for tailored release profiles.

### Which molecules can we work with?

**Examples of Oligonucleotides**

- RNA and DNA fragments
- Antisense oligonucleotides (ASO)
- Aptamers

## The benefits of using SynBiosys® for oligonucleotides

- Applicable across oligonucleotides and chemically modified oligonucleotides e.g. antisense oligonucleotides (ASO) or aptamers
- Protects API bioactivity by preserving structural integrity; also protects from physiological degradation e.g. enzymatic digestion
- Low burst and tunable release durations, from several days up to 3 months
- High encapsulation efficiency (>80%)
- High API loadings compared to other formulation technologies (up to 20-30%)
- Customisable formulations to optimise each drug product’s desired characteristics for efficacy and tolerability

- Fully biocompatible and safe, with an extensive biocompatibility / toxicity data package
- Easy-to-scale for manufacturing
- Less API required vs traditional formulations, therefore, reducing cost of goods and environmental footprint
- Developed with LAI microspheres – injected subcutaneous, intramuscular or local (such as intra-articular)
- Therapeutic focus: oncology, cardiovascular, CNS, rare diseases, infectious diseases, liver disease, ophthalmology, pulmonary & inflammatory disease, musculoskeletal disorders

[Discover SynBiosys®](https://innocorepharma.com/technologies/synbiosys/)

"*" indicates required fields

More About Innocore

[About Explore Innocore](https://innocorepharma.com/company/)

[Technologies Discover our technologies](https://innocorepharma.com/technologies/)

[Partnering Partner with us](https://innocorepharma.com/company/partnering-with-innocore/)